DB:0IT

Stock Analysis Report

Executive Summary

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has iCo Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0IT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-17.9%

0IT

-4.3%

DE Biotechs

-4.7%

DE Market


1 Year Return

-13.5%

0IT

5.5%

DE Biotechs

8.3%

DE Market

Return vs Industry: 0IT underperformed the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: 0IT underperformed the German Market which returned 8.3% over the past year.


Shareholder returns

0ITIndustryMarket
7 Day-17.9%-4.3%-4.7%
30 Day-16.9%-6.7%-4.0%
90 Day-15.8%0.4%-1.4%
1 Year-13.5%-13.5%5.8%5.5%11.7%8.3%
3 Year60.0%60.0%40.9%39.4%11.4%1.6%
5 Year540.0%540.0%10.9%8.6%15.1%-0.7%

Price Volatility Vs. Market

How volatile is iCo Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is iCo Therapeutics undervalued compared to its fair value and its price relative to the market?

6.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 0IT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 0IT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 0IT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 0IT is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0IT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0IT is overvalued based on its PB Ratio (6.8x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is iCo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iCo Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has iCo Therapeutics performed over the past 5 years?

8.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 0IT is currently unprofitable.

Growing Profit Margin: 0IT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 0IT is unprofitable, but has reduced losses over the past 5 years at a rate of 8.3% per year.

Accelerating Growth: Unable to compare 0IT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0IT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 0IT has a negative Return on Equity (-110.62%), as it is currently unprofitable.


Next Steps

Financial Health

How is iCo Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 0IT's short term assets (CA$1.8M) exceed its short term liabilities (CA$403.0K).

Long Term Liabilities: 0IT has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 0IT is debt free.

Reducing Debt: 0IT has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 0IT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 0IT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0IT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 0IT has less than a year of cash runway if free cash flow continues to grow at historical rates of 23.6% each year.


Next Steps

Dividend

What is iCo Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 0IT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 0IT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0IT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0IT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0IT's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

13.7yrs

Average management tenure


CEO

Andrew Rae (52yo)

15yrs

Tenure

CA$205,100

Compensation

Mr. Andrew J. Rae, BSc, MBA, Co-founded ICo Therapeutics Inc. in 2005 and serves as its Chief Executive Officer and President since February 2005. Mr. Rae serves as a Consultant to Ventures West Management ...


CEO Compensation Analysis

Compensation vs Market: Andrew's total compensation ($USD154.53K) is below average for companies of similar size in the German market ($USD414.81K).

Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Andrew Rae
Co-Founder15yrsCA$205.10k3.28% CA$209.6k
Michael Liggett
CFO, Corporate Secretary & Director3.1yrsCA$50.35kno data
Peter Hnik
Chief Medical Officer13.7yrsCA$200.04kno data

13.7yrs

Average Tenure

59yo

Average Age

Experienced Management: 0IT's management team is seasoned and experienced (13.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Andrew Rae
Co-Founder15yrsCA$205.10k3.28% CA$209.6k
Michael Liggett
CFO, Corporate Secretary & Director3.1yrsCA$50.35kno data
Julia Levy
Member of the Strategic Advisory Board14.3yrsno datano data
Richard Glickman
Member of the Strategic Advisory Board14.3yrsno datano data
William Jarosz
Chairman of the Board11.6yrsno data0.46% CA$29.2k
David Boyer
Member of the Clinical Advisory Board13.3yrsno datano data
Jason Slakter
Member of Clinical Advisory Board0yrsno datano data
Alan Bird
Member of the Clinical Advisory Board13.9yrsno datano data
Philip Rosenfeld
Member of Clinical Advisory Board13.7yrsno datano data
Donald Buell
Chairman of the Scientific Advisory Board0yrsno datano data

13.8yrs

Average Tenure

61yo

Average Age

Experienced Board: 0IT's board of directors are seasoned and experienced ( 13.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.3%.


Top Shareholders

Company Information

iCo Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: iCo Therapeutics Inc.
  • Ticker: 0IT
  • Exchange: DB
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$9.225m
  • Listing Market Cap: CA$6.381m
  • Shares outstanding: 153.75m
  • Website: https://www.icotherapeutics.com

Number of Employees


Location

  • iCo Therapeutics Inc.
  • 777 Hornby Street
  • 6th Floor
  • Vancouver
  • British Columbia
  • V6Z 1S4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ICOTSXV (TSX Venture Exchange)YesCommon SharesCACADJan 2008
ICOT.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 2008
0ITDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2008

Biography

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in clinical stage for the treatment of systemic fungal and parasitic infections. The company was founded in 2005 and is headquartered in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 22:29
End of Day Share Price2020/02/25 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.